A detailed history of China Universal Asset Management Co., Ltd. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 20,161 shares of RVNC stock, worth $51,813. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,161
Previous 12,271 64.3%
Holding current value
$51,813
Previous $31,000 64.52%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.57 - $2.57 $20,277 - $20,277
7,890 Added 64.3%
20,161 $51,000
Q2 2024

Jul 19, 2024

SELL
$2.34 - $4.73 $11,021 - $22,278
-4,710 Reduced 27.74%
12,271 $31,000
Q1 2024

Apr 29, 2024

BUY
$4.65 - $9.31 $31,740 - $63,550
6,826 Added 67.22%
16,981 $84,000
Q4 2023

May 21, 2024

SELL
$5.81 - $11.2 $39,659 - $76,451
-6,826 Reduced 40.2%
10,155 $89,000
Q4 2023

Jan 23, 2024

BUY
$5.81 - $11.2 $45,928 - $88,536
7,905 Added 351.33%
10,155 $89,000
Q3 2023

May 21, 2024

BUY
$11.47 - $25.07 $13,167 - $28,780
1,148 Added 104.17%
2,250 $25,000
Q3 2023

Oct 30, 2023

BUY
$11.47 - $25.07 $13,167 - $28,780
1,148 Added 104.17%
2,250 $26,000
Q2 2023

May 21, 2024

SELL
$24.7 - $37.61 $494 - $752
-20 Reduced 1.78%
1,102 $27,000
Q2 2023

Jul 27, 2023

SELL
$24.7 - $37.61 $494 - $752
-20 Reduced 1.78%
1,102 $28,000
Q1 2023

May 21, 2024

BUY
$18.36 - $35.27 $5,250 - $10,087
286 Added 34.21%
1,122 $36,000
Q1 2023

Apr 27, 2023

BUY
$18.36 - $35.27 $5,250 - $10,087
286 Added 34.21%
1,122 $36,000
Q4 2022

May 21, 2024

SELL
$18.32 - $30.66 $295,776 - $495,005
-16,145 Reduced 95.08%
836 $15,000
Q4 2022

Jan 31, 2023

BUY
$18.32 - $30.66 $2,784 - $4,660
152 Added 22.22%
836 $15,000
Q3 2022

Oct 21, 2022

BUY
$14.33 - $28.47 $9,801 - $19,473
684 New
684 $18,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.